Increasing Leqembi® royalties and new partnership with Novartis STOCKHOLM, Aug. 28, 2025 /PRNewswire/ -- Events during the second quarter 2025 The European Commission granted Marketing Authorisation (MA) for Leqembi® (lecanemab), triggering a milestone payment of EUR 20 M from Eisai The...
Hence then, the article about bioarctic interim report for the period april june 2025 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( BioArctic: Interim Report for the period April - June 2025 )
Also on site :
- Did 'Summer House: The Aftermath' Just Hard Launch Amanda Batula's Redemption Arc? Some Fans Say 'Too Late'
- A Shocking Recoupling! And the Second Vote Opens! Who Are the New Couples of ‘Love Island USA’ 2026
- Musk’s Grok AI helped fire 2,000 missiles at Iran – Pentagon